NCT02023463View on ClinicalTrials.gov

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 2, 2014

Primary Completion Date

July 10, 2017

Study Completion Date

January 1, 2040

Conditions
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

Enzalutamide

Given PO

DRUG

Goserelin acetate

Given SC

DRUG

Leuprolide acetate

Given IM or SC

RADIATION

Radiation therapy

Undergo image-guided radiation therapy

Trial Locations (1)

19107

Thomas Jefferson University, Philadelphia

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma Inc

INDUSTRY

collaborator

Medivation, Inc.

INDUSTRY

lead

Thomas Jefferson University

OTHER